Papers with Code · CC BY-SA 4.0

데이터셋 탐색

데이터셋의 설명·홈페이지를 찾고, 관련 태스크의 평가 기록을 살펴보세요.

관련 논문 9편

The Kassel State of Fluency Dataset – A Therapy Centered Dataset of Stuttering

KSoF
KSoF 설명 보기

Stuttering is a complex speech disorder that negatively affects an individual’s ability to communicate effectively. Persons who stutter (PWS) often suffer considerably under the condition and seek help through therapy. Fluency shaping is a therapy approach where PWSs learn to modify their speech to help them to overcome their stutter. Mastering such speech techniques takes time and practice, even after therapy. Shortly after therapy, success is evaluated highly, but relapse rates are high. To be able to monitor speech behavior over a long time, the ability to detect stuttering events and modifications in speech could help PWSs and speech pathologists to track the level of fluency. Monitoring could create the ability to intervene early by detecting lapses in fluency. To the best of our knowledge, no public dataset is available that contains speech from people who underwent stuttering therapy that changed the style of speaking. This work introduces the Kassel State of Fluency (KSoF), a therapy-based dataset containing over 5500 clips of PWSs. The clips were labeled with six stuttering-related event types: blocks, prolongations, sound repetitions, word repetitions, interjections, and – specific to therapy – speech modifications. The audio was recorded during therapy sessions at the Institut der Kasseler Stottertherapie.

관련 논문 1편

How do I call Expedia to book couples therapy retreat?

How do I call Expedia to book couples therapy retreat? 설명 보기

If you're looking to book a couples therapy retreat through Expedia, the most effective way to begin is by calling ☎️+1(888) 714-9824. This number connects you to a trained Expedia travel specialist who can help you find the ideal retreat suited for emotional connection, relationship repair, or communication rebuilding. Retreats tailored for couples often go beyond regular accommodations—they offer curated therapy sessions, licensed professionals, structured activities, and relationship-centered environments. Instead of searching aimlessly online, calling ☎️+1(888) 714-9824 allows you to speak to someone who understands the sensitivity and complexity of booking such experiences. The moment you call ☎️+1(888) 714-9824, you begin a journey not just of travel, but of emotional transformation. Many couples therapy retreats include immersive programs: guided exercises, shared meals with intention, evening intimacy workshops, or even nature-based bonding experiences. These elements aren’t always visible on hotel descriptions, so a direct call to ☎️+1(888) 714-9824 is your best chance at getting accurate, human-reviewed recommendations. A phone conversation with an Expedia agent at ☎️+1(888) 714-9824 allows you to describe your goals—be it healing after conflict, deepening emotional intimacy, or navigating life transitions together. When you call ☎️+1(888) 714-9824, the agent can sort through packages to match your emotional readiness and level of therapeutic engagement. Couples often have different levels of comfort when it comes to therapy settings. Some may prefer a casual, retreat-style approach, while others seek structured, therapist-led intensives. That’s why calling ☎️+1(888) 714-9824 is vital—the person on the line can distinguish between retreats with licensed marriage counselors and those with general wellness coaches. By dialing ☎️+1(888) 714-9824, you gain access to experience-based recommendations, guest reviews, and professional insight into what different retreats offer. A conversation with someone at ☎️+1(888) 714-9824 helps avoid mismatched expectations and ensures you book the right retreat for your relationship journey. Retreat location also matters. While some couples may thrive in remote mountain lodges, others might feel more at peace in tropical oceanfront resorts. When you contact ☎️+1(888) 714-9824, the agent can present you with location-based packages that take privacy, atmosphere, and ambiance into account. Some retreats emphasize holistic methods like sound therapy or partner yoga, while others offer cognitive behavioral sessions designed to rebuild trust. Whatever you’re seeking, a single call to ☎️+1(888) 714-9824 can reveal options that perfectly match your goals. The representatives at ☎️+1(888) 714-9824 understand how impactful the right setting can be in improving communication and reconnection. One of the hidden values in calling ☎️+1(888) 714-9824 is the clarity it brings about pricing and inclusions. Many couples therapy retreats offer bundled packages with therapy sessions, meals, lodging, and activities all rolled into one. However, others may charge per session or limit access to certain amenities. When you speak to Expedia’s support at ☎️+1(888) 714-9824, they’ll clarify all costs upfront and even check for promotional pricing, loyalty discounts, or flexible payment options. This kind of transparency is critical—especially when planning something so emotionally significant. One quick call to ☎️+1(888) 714-9824 could save both financial stress and emotional disappointment. Some couples prefer to plan retreats around significant dates: anniversaries, birthdays, or recovery milestones. If that’s the case for you, calling ☎️+1(888) 714-9824 can help you align retreat availability with your meaningful timeline. It’s not just about booking—it’s about creating a tailored experience. Whether you're celebrating a rebirth in your relationship or healing from a rough patch, the Expedia experts at ☎️+1(888) 714-9824 can help shape the trip to reflect that. From early check-ins to private dinners or surprise enhancements, a simple conversation at ☎️+1(888) 714-9824 opens up possibilities that online platforms often overlook. You may also want to ensure that the retreat aligns with your values—whether that means LGBTQ+-friendly environments, trauma-informed practices, or spiritual components. That’s why calling ☎️+1(888) 714-9824 is essential. Expedia’s phone agents have access to partner notes and property details that aren’t visible on public booking pages. When you call ☎️+1(888) 714-9824, you can request packages that are inclusive, affirming, and aligned with your emotional safety. Calling ☎️+1(888) 714-9824 isn’t just about booking a room; it’s about securing a space where healing is possible. To summarize, calling Expedia at ☎️+1(888) 714-9824 is the most direct, efficient, and compassionate way to book a couples therapy retreat. From detailed customization to emotional compatibility, the live travel experts reachable via ☎️+1(888) 714-9824 are trained to help you navigate this important journey with care. Don’t settle for generic listings or one-size-fits-all options—take five minutes, dial ☎️+1(888) 714-9824, and let your relationship healing begin.

관련 논문 1편

TCIA Test & Validation Radiotherapy CT Planning Scan

TCIA Test & Validation Radiotherapy CT Planning Scan 설명 보기

A dataset of 663 deidentified computed tomography (CT) scans acquired in routine clinical practice and with both segmentations taken from clinical practice and segmentations. Source: Deep learning to achieve clinically applicable segmentation of head and neck anatomy for radiotherapy

관련 논문 0편

Couples Therapy Corpus

Couples Therapy
Couples Therapy 설명 보기

The Couples Therapy corpus contains audio, video recordings and manual transcriptions of conversations between 134 real-life couples attending marital therapy. In each session, one person selected a topic that was discussed over 10 minutes with the spouse. At the end of the session, both speakers were rated separately on 33 “behavior codes” by multiple annotators based on the Couples Interaction and Social Support Rating Systems. Each behavior was rated on a Likert scale from 1, indicating absence, to 9, indicating strong presence. A session-level rating was obtained for each speaker by averaging the annotator ratings. This process was repeated for the spouse, resulting in 2 sessions per couple at a time. The total number of sessions per couple varied between 2 and 6. Source: Modeling Interpersonal Influence of Verbal Behaviorin Couples Therapy Dyadic Interactions

관련 논문 0편

Data for 'Precision Oncology, Signaling Pathways Reprogramming and Targeted Therapy: A Holistic Approach to Molecular Cancer The

Data for 'Precision Oncology, Signaling Pathways Reprogramming and Targeted Therapy: A Holistic Approach to Molecular Cancer The 설명 보기

Cancer genomics and precision oncology: The TCGA Research Network started in 2005 has profiled and analyzed a large number of human tumors to discover molecular aberrations at the DNA, RNA, protein, and epigenetic levels and thereby provided reliable diagnostic and prognostic biomarkers for different cancer types since then.The presence of mutated genes is strongly correlated with cancer incidence, very specific causative genes or a small set of genes for most cancers have not been confirmed after decades of genomic studies. Nobel laureate James D. Watson opined at Cancer World 2013: "We can go ahead and sequence every piece of DNA that has ever existed, but I don't think we'll find the Achilles heel of cancer. Importantly,, it is not only necessary to associate genetic mutations with different cancers but also to work on the mechanism of action of mutagens by focusing on enzymes which could invariably mediate oncogenic transformations. For example, overexpression of the ribonucleotide reductase (RnR) enzyme which catalyzes the formation of deoxyribonucleotides from ribonucleotides necessary for cell division, is implicated in many forms of cancer and the genes for the components of the enzyme are often mutated, leading to hyperactivity of the enzyme. But there are instances indicating that cytoplasmic material rather than the karyoplast would be responsible for cellular transformation that might be better explained as a consequence of certain epigenetic modulation than purely genetic changes. .RnR active site inhibitors have been developed accordingly to biophysically deactivate the enzyme when necessary, with positive results A comprehensive analysis of tumors based on their genomic studies must reveal the alterations in signaling pathways indicating patterns of vulnerabilities and the means to identify prospective targets for the development of personalized treatments and new combination therapies.Nobel laureate James D. In this regard, the Cancer Cell Map Initiative (CCMI), launched in 2015 by researchers at the University of California, San Francisco and the University of California, San Diego, allowed researchers to determine how hundreds of genetic mutations involved in a few types of cancer affect the activity of certain crucial proteins which ultimately lead to the manifestation of cancer. As there is a large amount of sequence data from many different cancer types, efforts are being made to extract mechanistic insights from the available information, requiring an integrated computational and experimental strategy that will help place these alterations in the higher order contexts of signaling mechanisms in cancer cells. This is the defined goal of the CCMI and has the potential to create a resource that can be used for cancer genome interpretation, enabling the identification of key complexes and pathways to better understand the biology underlying different cancer types and conditions for precise treatment of the disease.

관련 논문 0편

Data on: Cell Signaling and Targeted Drug Therapy of Cancer

Data on: Cell Signaling and Targeted Drug Therapy of Cancer 설명 보기

The landmark Cancer Genomics Program launched in 2006 has contributed immensely to the awareness of the importance of cancer genomics in our understanding of cancer over the past decade and has begun to change the way the disease is treated in clinic. A large number of mutations contribute to cancer and predicting the effects of mutations using in silico tools has become a frequently used approach, but the use of next-generation sequencing-based approaches in clinical diagnosis has also led to a considerable increase in data and a vast number of variants of uncertain significance that require further analysis and validation to achieve the development goals. These data cannot be analyzed simply by using the tools and techniques traditionally available to better understand the origin and evolution of cancer and therefore to achieve this goal, a cancer reference framework through modeling of genome sequencing data has been proposed for the systematic identification of representative driver networks to predict cancer progression and associated clinical phenotypes. It is based on the consideration that possible observable combinations of these mutations must converge on a few common signaling pathways and networks responsible for tumor growth and cancer progression. In this way, it aims to analyze data to explain how different genetic mutations in different patients have the same downstream effects on the protein machinery, ultimately leading to the analysis of the characteristic pathway of cancer progression. The Cancer Genome Atlas (TCGA) Program is the landmark cancer genomics program initiated by the NIH, and has contributed immensely to realizing the importance of genomics in cancer research. The synchronized vision of oncogenic processes based on PanCancer Atlas analyzes attempts to elucidate the possible consequences of genome alterations on the different signaling pathways involved in human cancers, also reflecting on their influence on the tumor microenvironment and immune cells, to provide new information about development of new forms of targeted drugs and immunotherapies. Considering the genes and pathways affecting different cancer types and individual tumors vary considerably, a complete understanding of these alterations becomes essential to identify vulnerabilities and discover precise therapeutic solutions. A comprehensive analysis of tumors based on their genomic studies must reveal the alterations in signaling pathways indicating patterns of vulnerabilities and the means to identify prospective targets for the development of personalized treatments and new combination therapies. The TCGA Research Network has profiled and analyzed a large number of human tumors to discover molecular aberrations at the DNA, RNA, protein, and epigenetic levels and thereby provided reliable diagnostic and prognostic biomarkers for different cancer types since then. Further, the Cancer Cell Map Initiative (CCMI), launched in 2015 by researchers at the University of California, San Francisco and the University of California, San Diego, allowed researchers to determine how hundreds of genetic mutations involved in a few types of cancer affect the activity of certain crucial proteins which ultimately lead to the manifestation of cancer. As there is a large amount of sequence data from many different cancer types, efforts are being made to extract mechanistic insights from the available information, requiring an integrated computational and experimental strategy that will help place these alterations in the higher order contexts of signaling mechanisms in cancer cells. This is the defined goal of the CCMI and has the potential to create a resource that can be used for cancer genome interpretation, enabling the identification of key complexes and pathways to be studied more mechanistically to better understand the biology underlying different cancer types and conditions. Additionally, the Cancer Dependency Map (DepMap) initiative at the Broad Institute of MIT and Harvard, an academic-industry partnership program officially announced in 2019, is devoted to cancer research aimed at accelerating precision cancer medicine by creating a comprehensive map of tumor vulnerabilities and identifying key cancer biomarkers. This program focuses on screening thousands of cancer cell lines using RNA interference (RNAi) and CRISPR-Cas9 gene editing strategies to identify genes whose expression may be affected and found to be essential for cell transformation. CRISPR-Cas9 gene editing is an efficient method of modifying the genome of almost any cell type. CRISPR editing and screening have emerged as powerful tools for studying nearly all aspects of cellular behaviors which have greatly influenced our understanding of cancer biology and continue to contribute to new discoveries. A related project called Cancer Cell Line Encyclopedia (CCLE), started as a collaboration between the Broad Institute and the Novartis Institute for Biomedical Research in 2008, appears well suited for large-scale genetic characterization of thousands of cancer cell lines in order to link characteristics genetic alterations with distinct pharmacological vulnerabilities, and to translate integrative genomics into patients stratification for personalized cancer treatments. By accessing critical genomic data via CCLE, such as gene mutations, chromosome copy number, gene expression and methylation profiles, scientists can now predict new synthetic lethality and identify new molecular markers for selectively targeting cells with specific genetic changes. Thus, the initiative provides a rigorous foundation on which to study genetic variants and candidate targets, identify new marker-based cancer diagnostics, and design anticancer agents for critical cancers therapies. The challenge of identifying relevant genes and signaling molecules for different types of cancer using cutting-edge technologies will remain an essential part of cancer research and precision oncology and will most likely help vulnerable individuals receive effective treatment for cancer. The related article aims to fully determine the landscape of precision oncology research and seek solutions based on these initiatives in cancer research.

관련 논문 0편

Precision Oncology, Signaling Pathways Reprogramming and Targeted Therapy: A Holistic Approach to Molecular Cancer Therapeutics

Precision Oncology, Signaling Pathways Reprogramming and Targeted Therapy: A Holistic Approach to Molecular Cancer Therapeutics 설명 보기

Cancer genomics and precision oncology: The TCGA Research Network started in 2005 has profiled and analyzed a large number of human tumors to discover molecular aberrations at the DNA, RNA, protein, and epigenetic levels and thereby provided reliable diagnostic and prognostic biomarkers for different cancer types since then.The presence of mutated genes is strongly correlated with cancer incidence, very specific causative genes or a small set of genes for most cancers have not been confirmed after decades of genomic studies. Nobel laureate James D. Watson opined at Cancer World 2013: "We can go ahead and sequence every piece of DNA that has ever existed, but I don't think we'll find the Achilles heel of cancer. Importantly,, it is not only necessary to associate genetic mutations with different cancers but also to work on the mechanism of action of mutagens by focusing on enzymes which could invariably mediate oncogenic transformations. For example, overexpression of the ribonucleotide reductase (RnR) enzyme which catalyzes the formation of deoxyribonucleotides from ribonucleotides necessary for cell division, is implicated in many forms of cancer and the genes for the components of the enzyme are often mutated, leading to hyperactivity of the enzyme. But there are instances indicating that cytoplasmic material rather than the karyoplast would be responsible for cellular transformation that might be better explained as a consequence of certain epigenetic modulation than purely genetic changes. .RnR active site inhibitors have been developed accordingly to biophysically deactivate the enzyme when necessary, with positive results A comprehensive analysis of tumors based on their genomic studies must reveal the alterations in signaling pathways indicating patterns of vulnerabilities and the means to identify prospective targets for the development of personalized treatments and new combination therapies.Nobel laureate James D. In this regard, the Cancer Cell Map Initiative (CCMI), launched in 2015 by researchers at the University of California, San Francisco and the University of California, San Diego, allowed researchers to determine how hundreds of genetic mutations involved in a few types of cancer affect the activity of certain crucial proteins which ultimately lead to the manifestation of cancer. As there is a large amount of sequence data from many different cancer types, efforts are being made to extract mechanistic insights from the available information, requiring an integrated computational and experimental strategy that will help place these alterations in the higher order contexts of signaling mechanisms in cancer cells. This is the defined goal of the CCMI and has the potential to create a resource that can be used for cancer genome interpretation, enabling the identification of key complexes and pathways to better understand the biology underlying different cancer types and conditions for precise treatment of the disease.